LeMaitre Vascular, Inc.
Every calculator, already run for LMAT
Open the full toolkit →You have the numbers on LMAT. Get the argument.
A written report on which of these readings actually decide the outcome for LeMaitre Vascular, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering LMATAnalyst Price Target Disagreement for LeMaitre Vascular, Inc.
Wall Street's bull case implies +67% from the current price; the bear case implies +3%. A 65% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for LMAT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biolog…
LMAT — frequently asked
Is LMAT a buy right now?
Wall Street's consensus rating on LeMaitre Vascular, Inc. is Buy across 8 analysts, with a mean price target of $107.00 (+36% vs. the current $78.87). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LMAT overvalued?
LMAT trades at 27.6x trailing earnings, against a DCF fair value of $73 per share. The current price implies 7% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LMAT's next earnings date?
LeMaitre Vascular, Inc. is next scheduled to report earnings around Nov 5, 2026. A full LMAT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for LeMaitre Vascular, Inc.?
Analysts covering LeMaitre Vascular, Inc. (LMAT) range from a bear-case target of $81.00 to a bull-case high of $132.00, with a mean consensus target of $107.00 across 7 analysts. The spread of $51.00 (65% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare LeMaitre Vascular, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For LeMaitre Vascular, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LMAT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on LeMaitre Vascular, Inc., in minutes. 3 free reports included with every account — no credit card required.